To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.
Eligibility
Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria:
1. Women aged 20-40 years;
2. Body Mass Index(BMI) ≥ 28kg/m2;
3. Women who intend to undergo frozen-thawed embryo transfer;
4. At least one embryo available for transfer;
5. Be capable of giving informed consent.
Exclusion Criteria:
1. Women who have been diagnosed with diseases affecting uterine cavity or endometrial receptivity;
2. Presence of endocrine disorders that may significantly affect body weight;
3. Use of drugs that may cause significant weight changes within 8 weeks before screening;
4. Presence of contraindications to the use of dual GIP/GLP-1 receptor agonist;
5. Previous bariatric surgery (e.g., gastric bypass) or planning to undergo such surgery during the study period;
6. Serum triglycerides (TG) \> 5.64mmol/L;
7. Calcitonin≥50 ng/L;
8. Presence of medical contraindications to assisted reproductive technology and/or pregnancy;
9. Any other condition considered inappropriate for participation by the investigator.
Primary outcome measure(s)
Good birth outcome rate — at delivery good birth outcome is defined as live birth(s) at ≥37 weeks, with infant birth weight between 2500 and 4000g and without a major congenital anomaly.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.